Skip to content

Study · Not a test of the peptide alone · 2020

3 results

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report.

Liang B, Chen J, Li T, Wu H, Yang W, Li Y, Li J, Yu C, Nie F, Ma Z, Yang M, Xiao M and 4 more

Show all authors

Nie P, Gao Y, Qian C, Hu M

Medicine1 Jul 2020Cited by 242 (Europe PMC)

PMID32756149 (opens in a new tab)PMCIDPMC7402800 (opens in a new tab)DOI10.1097/md.0000000000021429 (opens in a new tab)PepBankPUB-32756149
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

RationaleThe COVID-19 cases increased very fast in January and February 2020. The mortality among critically ill patients, especially the elder ones, is relatively high. Considering many patients died of severe inflammation response, it is urgent to develop effective therapeutic strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown good capabilities to modulate the immune response and repair the injured tissue. Therefore, investigating the potential of hUCMSCs to the treatment of COVID-19 critically ill patients is necessary.Patient concernsA 65-year-old woman felt fatigued and had a fever with body temperature of 38.2C, coughed up white foaming sputum. After 1 day, she had chest tightness with SPO2 of 81%, and blood pressure of 160/91 mm Hg.DiagnoseAccording to the guideline for the diagnosis and treatment of 2019 novel coronavirus infected pneumonia (Trial 4th Edition), COVID-19 was diagnosed, based on the real-time RT-PCR test of SARS-CoV-2.InterventionsAfter regular treatment for 12 days, the inflammation symptom of the patient was still very severe and the potential side effects of corticosteroid were observed. Then, allogenic hUCMSCs were given 3 times (5 × 10 cells each time) with a 3-day interval, together with thymosin α1 and antibiotics daily injection.OutcomesAfter these treatments, most of the laboratory indexes and CT images showed remission of the inflammation symptom. The patient was subsequently transferred out of ICU, and the throat swabs test reported negative 4 days later.LessonsThese results indicated the clinical outcome and good tolerance of allogenic hUCMSCs transfer.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In one critically ill woman with COVID-19, a regimen of stem cells, thymosin α1 and antibiotics was followed by remission of inflammation in most laboratory indexes and CT images.

    In plain wordsIn one critically ill woman with COVID-19, inflammation eased after a combined treatment that included thymosin α1.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseInflammation indexes and CT images
    Study

    n = 1

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    After these treatments, most of the laboratory indexes and CT images showed remission of the inflammation symptom.
    2 context sentences
    Summary · context
    A 65-year-old woman felt fatigued and had a fever with body temperature of 38.2C, coughed up white foaming sputum.
    Summary · context
    Then, allogenic hUCMSCs were given 3 times (5 × 10 cells each time) with a 3-day interval, together with thymosin α1 and antibiotics daily injection.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In one critically ill woman with COVID-19, the patient moved out of the ICU after a regimen of stem cells, thymosin α1 and antibiotics.

    In plain wordsOne critically ill woman with COVID-19 left the ICU after a combined treatment that included thymosin α1.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableTransfer out of ICU
    Study

    n = 1

    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    The patient was subsequently transferred out of ICU
    2 context sentences
    Summary · context
    A 65-year-old woman felt fatigued and had a fever with body temperature of 38.2C, coughed up white foaming sputum.
    Summary · context
    Then, allogenic hUCMSCs were given 3 times (5 × 10 cells each time) with a 3-day interval, together with thymosin α1 and antibiotics daily injection.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In one critically ill woman with COVID-19, the throat swab test was negative 4 days after a regimen of stem cells, thymosin α1 and antibiotics.

    In plain wordsOne woman with COVID-19 had a negative throat swab test after a combined treatment that included thymosin α1.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableSARS-CoV-2 throat swab test
    Study

    n = 1

    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    the throat swabs test reported negative 4 days later
    2 context sentences
    Summary · context
    A 65-year-old woman felt fatigued and had a fever with body temperature of 38.2C, coughed up white foaming sputum.
    Summary · context
    Then, allogenic hUCMSCs were given 3 times (5 × 10 cells each time) with a 3-day interval, together with thymosin α1 and antibiotics daily injection.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.